



To: IPA Administrators and Medical Directors
From: IEHP – Provider Relations
Date: January 13, 2020
Subject: UM Authorization Guideline Updates

IEHP’s Utilization Management Subcommittee has approved the following authorization guidelines, effective 11/13/2019:

Guideline #	Guideline Title	Degree of Change	Revisions
UM_BH 06	Criteria for Multidisciplinary Diagnostic Treatment	New	<ul style="list-style-type: none"> • Diagnostic testing no longer required for BHT services • Latest research shows single provider can assess and diagnose children with autism. Multidisciplinary assessments are not necessary • Criteria differentiates when to refer for single provider assessment versus multidisciplinary assessment
UM_OTH 19	Reference Product Pegfilgrastim and Biosimilar Products	New	<ul style="list-style-type: none"> • Filphila (pegfilgrastim-jmdb) and Udenyca (pegfilgrastim-cbqv) are FDA-approved biosimilar products for the same indications as their reference product Neulasta • Per FDA, biosimilar has no clinically meaningful differences in terms of safety, purity and potency from reference product • NCCN endorsed pegfilgrastim biosimilar use in 2019 Hematopoietic Growth Factor clinical practice guideline • Filphila and Udenyca are preferred pegfilgrastim agents when MCG criteria are met
UM_OTH 05	Tertiary Care Center Referral Requests	Minor	<ul style="list-style-type: none"> • Addition of Loma Linda University Medical Center (LLUMC) to the list of tertiary care centers • LLUMC is the only contracted tertiary facility within the service area • As such, LLUMC should be considered first when medically appropriate

Guideline #	Guideline Title	Degree of Change	Revisions
UM_BH 04	Behavioral Health Treatment Applied Behavior Analysis for Qualified Autism Service Providers	Retired	<ul style="list-style-type: none"> • Previous guideline based off APL 15-025 • BHT was only for children with a diagnosis of ASD • Replaced by new UM Subcommittee Guideline # UM_BH 05, Behavioral Health Treatment Services
UM_DIA 09	Fractional Exhaled Nitric Oxide (FeNO)	Retired	<ul style="list-style-type: none"> • Medi-Cal Provider Manual recently developed guidelines for appropriate use and reimbursement of FeNO measurement • FeNO is not found in Medicare Local or National Coverage Determinations • Replacing the current UM Subcommittee Guideline with Medi-Cal Provider Manual section Respiratory Care, guideline Fractional Exhaled Nitrous Oxide (FeNO) (California Code of Regulations (CCR), Title 22, Section 51081. 1)
UM_ENT 03	Sleep Studies Prior to Tonsillectomy	Retired	<ul style="list-style-type: none"> • MCG Health Guidelines specify similar guidelines in two documents: <ul style="list-style-type: none"> ○ A-0145 Polysomnography (PSG), Sleep Center ○ A-0181 Tonsillectomy • A-0181 Tonsillectomy lists obstructive sleep apnea indicated by polysomnography findings as an indication for surgery • A-0145 Polysomnography defines clinical indications for a child, infant or neonate with suspected obstructive sleep apnea to have a sleep study if adenotonsillectomy is being considered for treatment. This guideline goes into more detail regarding use of a sleep study for purposes of diagnosis and preoperative risk assessment. Recommend retiring the current UM Subcommittee Guideline and replacing with MCG A-0145 and A-0181
UM_DIA 13	MRI of the Breast	Retired	<ul style="list-style-type: none"> • MCG Health Guidelines specify similar guidelines in A-0048 Breast MRI • The MCG Guideline goes into more detail regarding clinical indications for the procedure • Replacing the current UM Subcommittee Guideline with MCG A-0048

You may access these and all other authorization guidelines through the Provider portal.

Location: www.iehp.org > For Providers > Provider Resources > Utilization Management Criteria

As a reminder, all communications sent by IEHP can also be found on the Provider portal:

Location: www.iehp.org > For Providers > Plan Updates > Correspondences

If you have any questions, please do not hesitate to contact the IEHP Provider Relations Team at (909) 890-2054. Thank you.